Targeting folliculin to selectively inhibit mTORC1:a promising strategy for treating nonalcoholic fatty liver disease  

作　　者：Yan Ling Yanpeng Li Liang Li 

机构地区：[1]Changzheng Hospital,Naval Medical University,Shanghai 20003,People's Republic of China [2]National Center for Liver Cancer,Naval Medical University,Shanghai 201805,People's Republic of China

出　　处：《Signal Transduction and Targeted Therapy》2022年第9期3152-3154,共3页信号转导与靶向治疗（英文）

基　　金：State Key Project on Infectious Diseases of China(2018ZX10723204-002-002);National Natural Science Foundation of China(81672777,81671314,82002522,82172896);Shanghai Rising-Star Program(17QA1405700);Shanghai Top Young Talents Program,Research Program of Changzheng Hospital(2019CZJS102).

摘　　要：In a recent study published in Science,Bridget S.Gosis et al.demonstrate that selective inhibition of the mammalian target of rapamycin complex 1(mTORC1)signaling through deletion of the RagC/D guanosine triphosphatase-activating protein folliculin(FLCN)in mice enhances activation of transcription factor E3(TFE3)in the liver and protects against nonalcoholic fatty liver disease(NAFLD).

关 键 词：LIVER NAFLD 

分 类 号：R575.5[医药卫生—消化系统]